IMUC - ImmunoCellular Therapeutics Ltd

Industry: Biotechnology Sector: Healthcare Exchange: NYSE

IMUC - ImmunoCellular Therapeutics Ltd

Industry: Biotechnology Sector: Healthcare Exchange: NYSE

Tue 18'th Sep 2018

PERIOD 2018-06-19 - 2018-09-18
CHANGE 0.62%
PRICE $0.21





Request Prediction

ImmunoCellular Therapeutics Ltd Stock Analysis

Technical stock analysis for Tue 18'th Sep 2018

Sell candidate since 2018-09-05 Loss -10.20%
Shorts 10.80% ( 2018-08-31 )
Cash n/a
Loans n/a
Beta -0.08
ROA -209.11

ImmunoCellular Therapeutics Ltd gained 0.62% in the last trading day, rising from $0.21 to $0.21 The price has fallen in 7 of the last 10 days and is down by -12.32% for this period. Volume fell in the last day by -5 698 shares, and in total, 132 017 shares bought and sold for approximately $27 895.20. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes for the next couple of days.


ImmunoCellular Therapeutics Ltd lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -13.93% during the next 3 months and, with 90% probability hold a price between $0.17 and $0.20 at the end of this period.

Click here for today's Top 5 Trending Companies


A buy signal was issued from a pivot bottom point on Friday September 14, 2018, which indicates further gains until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. ImmunoCellular Therapeutics Ltd holds sales signals from both short- and long-term moving averages. In addition, there is a general sales signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up there will be some resistance from the lines at $0.22 and $0.23. A break-up above any of these levels will issue buy signals. Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may not be. The very low volume increases the risk and reduces the other technical signals issued.

Access today's Top 5 Golden Star Companies

Relative Strength Index (RSI)

The stock currently holds a RSI14 at 18 and is oversold on RSI14. The stock being oversold is no guarantee for instant reaction up as some stocks may be oversold for a long time. It is important to review the previous RSI-history to get an indication of the RSI-sensitiveness.

Access full RSI 14 and RSI 21 lists

Support & Resistance

ImmunoCellular Therapeutics Ltd finds support from accumulated volume at $0.21.

Support: $0.21 Price: $0.21 Resistance: $0.23


This stock may move much during a day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.01 between high and low, or 4.76%. For the last week the stock has had a daily average volatility of 6.24%.

ImmunoCellular Therapeutics Ltd is oversold on RSI14 (18). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.

Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.

Overall risk:

Very Low Low Medium High Very High


ImmunoCellular Therapeutics Ltd holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Sell Candidate

Click for Top 5 Sell Candidates
IMUC $0.21 $0.00(0.62%)
IMUC is up $0.00 today, but where's it headed in October?
Zacks Investment Research is releasing its prediction for IMUC based on the 1-3 month system that more than doubles the S&P 500.

Click here – the IMUC analysis is free »

Last donation

Do you find our website useful too?
Help us improve by making a small donation or
Get PRO features

Proudly made at

in partnership with